173 related articles for article (PubMed ID: 23771003)
1. Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT.
de Pagter PJ; Schuurman R; Keukens L; Schutten M; Cornelissen JJ; van Baarle D; Fries E; Sanders EA; Minnema MC; van der Holt BR; Meijer E; Boelens JJ
Bone Marrow Transplant; 2013 Nov; 48(11):1460-4. PubMed ID: 23771003
[TBL] [Abstract][Full Text] [Related]
2. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.
de Pagter PJ; Schuurman R; Visscher H; de Vos M; Bierings M; van Loon AM; Uiterwaal CS; van Baarle D; Sanders EA; Boelens J
Biol Blood Marrow Transplant; 2008 Jul; 14(7):831-9. PubMed ID: 18541204
[TBL] [Abstract][Full Text] [Related]
3. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study.
Dulery R; Salleron J; Dewilde A; Rossignol J; Boyle EM; Gay J; de Berranger E; Coiteux V; Jouet JP; Duhamel A; Yakoub-Agha I
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1080-9. PubMed ID: 22212513
[TBL] [Abstract][Full Text] [Related]
4. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.
Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K
Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656
[TBL] [Abstract][Full Text] [Related]
5. First analysis of human herpesvirus 6T-cell responses: specific boosting after HHV6 reactivation in stem cell transplantation recipients.
de Pagter AP; Boelens JJ; Scherrenburg J; Vroom-de Blank T; Tesselaar K; Nanlohy N; Sanders EA; Schuurman R; van Baarle D
Clin Immunol; 2012 Sep; 144(3):179-89. PubMed ID: 22820131
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for human herpesvirus 6 reactivation and its relationship with syndrome of inappropriate antidiuretic hormone secretion after stem cell transplantation in pediatric patients.
Toriumi N; Kobayashi R; Yoshida M; Iguchi A; Sarashina T; Okubo H; Suzuki D; Sano H; Ogata M; Azuma H
J Pediatr Hematol Oncol; 2014 Jul; 36(5):379-83. PubMed ID: 23929317
[TBL] [Abstract][Full Text] [Related]
7. Impact of Human Herpesvirus-6 Reactivation on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.
Aoki J; Numata A; Yamamoto E; Fujii E; Tanaka M; Kanamori H
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2017-22. PubMed ID: 26226409
[TBL] [Abstract][Full Text] [Related]
8. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
9. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation.
Wang LR; Dong LJ; Zhang MJ; Lu DP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1031-7. PubMed ID: 17067909
[TBL] [Abstract][Full Text] [Related]
10. Characterizing human herpes virus 6 following hematopoietic stem cell transplantation.
Perissinotti AJ; Gulbis A; Shpall EJ; Howell J
J Oncol Pharm Pract; 2015 Apr; 21(2):85-92. PubMed ID: 24407957
[TBL] [Abstract][Full Text] [Related]
11. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
12. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study.
Ogata M; Satou T; Kadota J; Saito N; Yoshida T; Okumura H; Ueki T; Nagafuji K; Kako S; Uoshima N; Tsudo M; Itamura H; Fukuda T
Clin Infect Dis; 2013 Sep; 57(5):671-81. PubMed ID: 23723198
[TBL] [Abstract][Full Text] [Related]
13. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
Peric Z; Cahu X; Chevallier P; Brissot E; Malard F; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Milpied N; Coste-Burel M; Imbert-Marcille BM; Mohty M
Leukemia; 2011 Jun; 25(6):932-8. PubMed ID: 21350556
[TBL] [Abstract][Full Text] [Related]
14. Human herpesvirus 6 infection after allogeneic stem cell transplantation: incidence, outcome, and factors associated with HHV-6 reactivation.
Jeulin H; Agrinier N; Guery M; Salmon A; Clément L; Bordigoni P; Venard V
Transplantation; 2013 May; 95(10):1292-8. PubMed ID: 23514960
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of Human Herpes Virus-6 After Pediatric Stem Cell Transplantation: Risk Factors, Onset, Clinical Symptoms and Association With Severity of Acute Graft-Versus-Host Disease.
Verhoeven DH; Claas EC; Jol-van der Zijde CM; Thijssen JC; Lankester AC; Bredius RG; Putter H; Kroes AC; Egeler RM; Schilham MW; van Tol MJ
Pediatr Infect Dis J; 2015 Oct; 34(10):1118-27. PubMed ID: 26132825
[TBL] [Abstract][Full Text] [Related]
16. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
Kalpoe JS; van der Heiden PL; Barge RM; Houtzager S; Lankester AC; van Tol MJ; Kroes AC
Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
[TBL] [Abstract][Full Text] [Related]
17. Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation.
Jaskula E; Dlubek D; Sedzimirska M; Duda D; Tarnowska A; Lange A
Transplant Proc; 2010 Oct; 42(8):3273-6. PubMed ID: 20970670
[TBL] [Abstract][Full Text] [Related]
18. Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation.
Wang LR; Dong LJ; Zhang MJ; Lu DP
Bone Marrow Transplant; 2008 Nov; 42(10):673-7. PubMed ID: 18695666
[TBL] [Abstract][Full Text] [Related]
19. Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis.
Ogata M; Satou T; Inoue Y; Takano K; Ikebe T; Ando T; Ikewaki J; Kohno K; Nishida A; Saburi M; Miyazaki Y; Ohtsuka E; Saburi Y; Fukuda T; Kadota J
Bone Marrow Transplant; 2013 Feb; 48(2):257-64. PubMed ID: 22750998
[TBL] [Abstract][Full Text] [Related]
20. Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation.
Admiraal R; de Koning CCH; Lindemans CA; Bierings MB; Wensing AMJ; Versluys AB; Wolfs TFW; Nierkens S; Boelens JJ
J Allergy Clin Immunol; 2017 Dec; 140(6):1643-1650.e9. PubMed ID: 28392330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
